Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of interaction with sodium channels.[A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.[A262681] It was granted approval by Health Canada in September 2010.[L49206]
In the US and Europe, lacosamide is indicated for the treatment of partial-onset seizures in children and adults.[L49191, L49196, L49201] In Canada, it is reserved for use in adults.[L49206] It is also used as an adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients four years of age and older.[L49191, L49201] The extended-release capsules of lacosamide are indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.[L49196]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
